Von Hippel-Lindau Disease: Clinical Update and New Drug Therapy

Von Hippel-Lindau (VHL) disease is a rare hereditary cancer syndrome caused by mutations in the VHL gene. These mutations predispose patients to the development of cysts and tumors in several systems and organs, including the central nervous system, retina, kidneys, pancreas, adrenal glands and reproductive organs. VHL is a complex disease that requires specialized advanced treatment from a multidisciplinary team of specialists.

In this Better Edge podcast episode, the following experts from the Northwestern Medicine Von Hippel-Lindau Disease Program discuss VHL and the clinical management for this patient population: Rimas V. Lukas, MD, Associate Professor of Neuro-Oncology; Niraj K. Shenoy, MD, PhD, MS, Associate Professor of Hematology/Oncology and of Pathology; and Brittany M. Szymaniak, PhD, CGC, Instructor of Urology. They share a recent Northwestern Medicine study published in Neuro-Oncology that examined belzutifan, the first approved HIF-2α inhibitor, in VHL-associated tumors.